Drug benefit program value-for-money audit

Each year, we are required under the Workplace Safety and Insurance Act (WSIA) to have an external firm review the cost, efficiency, and effectiveness of one of our programs through a value-for-money audit. The latest audit focused on our drug benefit program and was conducted by KPMG.


found our drug benefit program demonstrates moderate value for money. This means the program was found to be efficient and effective, while having some areas of opportunity in our communication and collaboration with the health care community and clarity of stakeholder roles. Our comprehensive drug coverage, drug formularies, partnership with TELUS Health, progressive cannabis policy and monitoring of opioid prescriptions were listed as some of the program’s core strengths.

The report outlined recommendations in five key areas: legislative and policy framework, program governance, service delivery and case management, strategic procurement and partnerships, and billing and payment.

We will use the recommendations to guide future business planning and make sure we continue to strengthen the drug benefit program and the services we provide to customers.